MedTrace Logo

Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer

NCT01671891 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-08-24

No results posted yet for this study

Summary

Rectal cancer is one of the most common malignant tumors in the world. However, there's also no reliable and sensitive method to monitor diseases and evaluate therapy responses till now. Circulating tumor cells, which could reflect tumor's status correctly and reliably, may be a promising method in this field. This study is to investigate the role of circulating tumor cells in evaluating and predicting the responses of chemoradiotherapy in rectal cancer.

Conditions

Interventions

RADIATION

radiation therapy

45-55Gy

DRUG

capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)

radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Completion
2013-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01671891 on ClinicalTrials.gov